Two isolated genes closely associated with breast and ovarian cancers are unpatentable, a New York federal judge ruled Monday. The judge decided that the two genes, once separated from the lengthy DNA sequence, cannot be considered sufficiently new and useful to be deemed patentable. The case was closely watched by the medical community and cancer patients who argued that the two genes in dispute, BRCA1 and BRCA2, should not be patented and privately owned.
March 30, 2010 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Two isolated genes closely associated with breast and ovarian cancers are unpatentable, a federal judge ruled Monday.
Southern District of New York Judge Robert W. Sweet decided that the two genes, once separated from the lengthy DNA sequence, cannot be considered sufficiently new and useful to be deemed patentable.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
